The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML).
 
Areej El-Jawahri
No Relationships to Disclose
 
Tanya Keenan
No Relationships to Disclose
 
Gregory Alan Abel
No Relationships to Disclose
 
David P. Steensma
Stock and Other Ownership Interests - ARIAD; Synta
Consulting or Advisory Role - Amgen; Celgene; Genoptix; Incyte; Novartis
 
Thomas William LeBlanc
Honoraria - Helsinn Therapeutics
Consulting or Advisory Role - Boehringer Ingelheim; Epi-Q
Research Funding - Helsinn Therapeutics (Inst); Opus Science/Celgene (Inst)
 
Lara Traeger
No Relationships to Disclose
 
Amir Tahmasb Fathi
No Relationships to Disclose
 
Daniel J. DeAngelo
No Relationships to Disclose
 
Martha Wadleigh
No Relationships to Disclose
 
Gabriela Hobbs
No Relationships to Disclose
 
Philip C. Amrein
No Relationships to Disclose
 
Richard M. Stone
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bristol-Myers Squibb; Celator; Celgene; Juno Therapeutics; Karyopharm Therapeutics; Merck; Roche/Genentech; Seagen; Sunesis Pharmaceuticals; Xenetic Biosciences
Research Funding - Agios (Inst); Celator (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Karen K. Ballen
No Relationships to Disclose
 
Yi-Bin Albert Chen
Honoraria - Bayer; Millennium
Consulting or Advisory Role - ARIAD; Millennium; Seagen
Research Funding - Bayer; Celgene; Novartis; Otsuka; Seagen
 
Jennifer S. Temel
Research Funding - Helsinn Therapeutics (Inst)
Travel, Accommodations, Expenses - Helsinn Therapeutics